B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.

Arthritis Res Ther · 2016 · PMC5116204 · PMID 27863504

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendp = 0.08so close (0.05 < p ≤ 0.1)

Quantitative analysis of the hand joints of all 20 patients showed a trend of higher 89 Zr-rituximab joint uptake in responders than in non-responders (SUV, p = 0.08; T/B ratio, p = 0.06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.